ArticleBMC infectious diseases2026
Jarisch-Herxheimer reaction as a complication of penicillin G and ceftriaxone treatment in neurosyphilis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundJarisch-Herxheimer reaction (JHR) is a complication of antibiotic treatment in neurosyphilis, and the profile of JHR in patients treated with different antibiotics remains unclear. This study investigates the incidence, clinical manifestations, and management of JHR in patients treated with penicillin G or ceftriaxone.
methodsA retrospective study was conducted at the Shanghai Skin Disease Hospital, China, involving 1010 inpatients diagnosed with neurosyphilis, among whom 103 developed JHR. Statistical analyses included Student’s t-test or Mann-Whitney test for continuous variables and Fisher’s exact test for categorical data.
resultsThe overall incidence of JHR among neurosyphilis patients was 10.20% (103/1010), with rates varying from 0% − 25% across different subtypes. Incidence was similar in penicillin G-treated (10.20%, 92/902) and ceftriaxone-treated (10.19%, 11/108) cohorts. The 92 JHR cases of penicillin G group manifested as fever (98.91%, 91/92) and neuropsychiatric symptoms (25%, 23/92). All 11 cases of JHR in the ceftriaxone group presented with fever (100%, 11/11). Penicillin G treatment resulted in an earlier fever onset (8.92 ± 4.98 h vs. 14.00 ± 5.90 h, 95% CI: 1.861 to 8.303, P < 0.05) and a shorter time to defervescence (16.35 ± 5.48 h vs. 20.80 ± 3.79 h, 95% CI: 1.085 to 7.848, P < 0.05) than ceftriaxone. Management strategies included physical cooling, indomethacin suppositories, and supportive treatment for neuropsychiatric symptoms. Neuropsychiatric symptoms of JHR resolved within 2–7 days of initiating antibiotic therapy.
conclusionsJHR is a notable complication of neurosyphilis treatment, presenting as febrile and neuropsychiatric symptoms. JHR frequency is comparable between penicillin G and ceftriaxone treatment. Penicillin G triggers an earlier febrile response of JHR compared to ceftriaxone. While generally mild and self-limiting, JHR can present with neuropsychiatric symptoms and severe conditions. This study contributes to the understanding of JHR and provides insights into the comparative effects of penicillin G and ceftriaxone treatment in neurosyphilis. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.